Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Patients with (any one of #1, #2, and/or #3):~  1. Suspicion of neuroendocrine tumors (NET) on axial imaging (computed tomography (CT)/magnetic resonance imaging (MRI)/fluorodeoxyglucose (FDG) positron emission tomography (PET) and/or~ 2. biochemical evidence of neuroendocrine tumor (serum/urinary) based on elevated levels of chromogranin A, pancreatic polypeptide, neuron-specific enolase, vasoactive intestinal polypeptide, serotonin (urinary 5-HIAA), gastrin, somatostatin, catecholamines, metanephrines, calcitonin, fasting insulin, C-peptide (proinsulin), glucagon and/or~ 3. familial predisposition to NET in patients with multiple endocrine neoplasia type 1 (MEN1) and Von Hippel-Lindau (VHL) (symptomatic and/or asymptomatic cases; with biochemical or anatomic imaging evidence of disease).~* Age greater than or equal to 10 years of age.~* For females: Negative urine pregnancy test OR post-menopausal for at least 2 years OR patient has had a hysterectomy.~* Patients must be willing to return to National Institutes of Health (NIH) for follow-up.~* Ability of subject or Legally Authorized Representative (LAR) (if the patient is deemed by the treating physician to be cognitively impaired or questionably impaired in such a way that the ability of the patient to give informed consent is questionable) to understand and the willingness to sign a written informed consent document indicating that they are aware of the investigational nature of this study.~EXCLUSION CRITERIA:~* Patients unwilling to undergo serial non-invasive imaging.~* Pregnant or lactating women: Pregnant women are excluded from this study because the effects of (68)Ga-DOTATATE in pregnancy are not known. Because there is an unknown but potential risk for adverse events in nursing infants secondary to administration of~  (68)Ga-DOTATATE in the mother, breastfeeding should be discontinued for at least one day if the mother receives (68)Ga-DOTATATE.~* Patients that have recognized concurrent active infection,~* Patients with the use of any investigational product or device, excluding 18F-dihydroxyphenylalanine (F-DOPA) scans, within 30 days prior to dosing.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 68Gallium DOTATATE imaging (Type: EXPERIMENTAL): 68Gallium DOTATATE imaging

Based on this trial design, predict the completion outcome and termination type (if applicable).